Target Audience: Retina Specialists & Pediatric Ophthalmologists
Source:American Academy of Ophthalmology (AAO) Ophthalmic Technology Assessment–2026
Executive Summary
While intravitreal anti-VEGF agents (bevacizumab, ranibizumab, aflibercept) are highly effective for primary treatment of Type 1 Retinopathy of Prematurity (ROP), systemic absorption and suppression of circulating VEGF have raised long-standing concerns regarding neonatal neurodevelopment.A comprehensive literature assessment published by the AAO systematically evaluated 26 comparative studies (4 articles on 3 Level II RCTs and 22 Level III comparative cohort studies) published across 39 countries from 2006 to 2022.
Key Takeaway: The majority of evidence (77% of studies, including all RCTs) demonstrates no statistically significant difference in long-term neurodevelopmental outcomes or IQ between infants treated with primary anti-VEGF therapy versus laser photocoagulation surgery (LPC).
Key Findings & Evidence Breakdown
1. Randomized Controlled Trials (Level II Evidence)
- Overall Outcome: None of the 3 RCTs (BEAT-ROP, RAINBOW, and FIREFLEYE next) found statistically significant differences in growth parameters (weight, length, head circumference) or standardized neurodevelopmental scores at 2 or 5 years.
- Ranibizumab (RAINBOW Extension): 5-year follow-up showed no significant differences in Mullen Scales of Early Learning T-scores or growth parameters compared to LPC.
- Aflibercept (FIREFLEYE Next): 2-year analysis revealed comparable Bayley-III and Vineland Adaptive Behavior scores between aflibercept and LPC cohorts.
2. Comparative Cohort Studies (Level III Evidence)
- 16 of 22 studies (73%) detected no difference in neurodevelopmental delay or cerebral palsy (CP) rates.
- Long-Term IQ Testing (>4 Years): 5 Asian studies evaluated Full-Scale IQ (WPPSI-IV / WISC-IV) at ages 3–12 years; 0% found a statistically significant difference between anti-VEGF and LPC.
- Discrepancies:
- 4 studies reported worse motor or language/social outcomes with bevacizumab.
- 2 studies reported worse cognitive/developmental scores with LPC.
- Context: Confounding by indication was prominent in cohort studies—sicker infants or those with more posterior/aggressive disease were disproportionately assigned to receive anti-VEGF.
Pharmacokinetic & Systemic Considerations
Different anti-VEGF agents vary substantially in systemic exposure and serum half-life:
- Bevacizumab (IVB): Longest systemic persistence; serum half-life is ~21 days. Suppresses free systemic VEGF levels up to 60 days post-injection.
- Ranibizumab (IVR): Apparent serum half-life is ~5.6 days. Plasma free VEGF levels show minimal to no suppression compared to LPC.
- Aflibercept (IVA): Rapid systemic clearance with transient peak at Day 1 followed by decline.
Critical Study Limitations
- Lack of Statistical Power: No included study was specifically powered to detect small differences in long-term neurodevelopmental outcomes.
- Confounding Bias: Non-randomized studies frequently selected anti-VEGF for sicker newborns unable to tolerate general anesthesia or operating room transport.
- Assessment Tools: Early testing (<24 months) gives a snapshot of functioning but offers lower predictive validity for school-age cognitive performance than testing beyond 4 years.
Practical Clinical Practice Takeaways
- Safety Reassurance: Current high-level evidence does not support the premise that anti-VEGF therapy inherently causes adverse neurodevelopmental outcomes compared to LPC.
- Holistic Treatment Selection: Decisions regarding primary ROP modality must be individualized based on:
- Ocular factors (zone I disease, aggressive ROP, media opacities).
- Systemic stability and ability to tolerate anesthesia/laser duration.
- Patient follow-up reliability (given the risk of late recurrence with anti-VEGF).
